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Abstract
RGS proteins are critical modulators of G protein-coupled receptor (GPCR) signaling given their
ability to deactivate Gα subunits via “GTPase-accelerating protein” (GAP) activity. Their
selectivity for specific GPCRs makes them attractive therapeutic targets. However, measuring
GAP activity is complicated by slow GDP release from Gα and lack of solution-phase assays for
detecting free GDP in the presence of excess GTP. To overcome these hurdles, we developed a
Gαi1 mutant with increased GDP dissociation and decreased GTP hydrolysis, enabling detection
of GAP activity using steady-state GTP hydrolysis. Gαi1(R178M/A326S) GTPase activity was
stimulated 6~12 fold by RGS proteins known to act on Gαi subunits, and not affected by those
unable to act on Gαi, demonstrating that the Gα/RGS domain interaction selectivity was not
altered by mutation. Gαi1(R178M/A326S) interacted with RGS proteins with expected binding
specificity and affinities. To enable non-radioactive, homogenous detection of RGS protein effects
on Gαi1(R178M/A326S), we developed a Transcreener® fluorescence polarization immunoassay
based on a monoclonal antibody that recognizes GDP with greater than 100-fold selectivity over
GTP. Combining Gαi1(R178M/A326S) with a homogenous, fluorescence-based GDP detection
assay provides a facile means to explore the targeting of RGS proteins as a new approach for
selective modulation of GPCR signaling.
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The standard model of GPCR signal transduction had long been restricted to a three-
component system: receptor, G-protein, and effector 1. The seven-transmembrane domain
receptor is coupled to a membrane-associated heterotrimeric complex composed of a GTP-
hydrolyzing Gα subunit and a Gβγ dimeric partner. Agonist-induced conformational
changes enhance the guanine nucleotide exchange activity of the receptor, leading to the
release of GDP (and subsequent binding of GTP) by the Gα subunit. On binding GTP,
conformational changes within the three `switch' regions of Gα allow the release of Gβγ.
Separated Gα·GTP and Gβγ subunits are then free to propagate intracellular signaling via
diverse effectors 2. The intrinsic GTP hydrolysis (GTPase) activity of Gα resets the cycle by
forming Gα·GDP which has low affinity for effectors but high affinity for Gβγ. In this way,
the inactive, GDP-bound heterotrimer (Gα·GDP/Gβγ) is reformed and capable once again to
interact with activated receptor.
Based on this cycle of receptor-catalyzed GTP exchange and intrinsic GTP hydrolysis by
Gα, the duration of heterotrimeric G-protein signaling is thought to be controlled by the
lifetime of the Gα subunit in its GTP-bound state. After the establishment of this basic
model 1, RGS proteins (“regulators of G-protein signaling”) were subsequently discovered
3–5 to bind Gα subunits (via a conserved ~120 amino-acid RGS domain) and dramatically
accelerate their intrinsic GTPase activity 6, thereby attenuating heterotrimer-linked
signaling. Nearly 40 human proteins contain at least one RGS domain, with many of these
proteins (e.g., RGS4, RGS16) serving as GTPase-accelerating proteins (GAPs) for Gαi/o
subunits, yet others such as RGS2 and p115-RhoGEF being particularly attuned to Gαq/11
and Gα12/13 substrates, respectively 7 . The discovery of this superfamily of Gα-directed
GAPs resolved apparent timing paradoxes between observed rapid physiological responses
mediated by GPCRs and the slow hydrolysis activity of the cognate G-proteins seen in vitro.
Thus, in this capacity as negative regulators of GPCR signal transduction, the RGS proteins
present themselves as excellent potential drug discovery targets 7. For example,
pharmacological inhibition of RGS domain GAP activity should lead to prolonged signaling
from G-proteins activated by agonist-bound GPCRs.
The most direct way to detect RGS protein function is by measuring the increased GTPase
activity exhibited by its target Gα protein. However, accurate in vitro measurements of Gα-
catalyzed GTP hydrolysis are difficult to obtain without laborious biochemical
reconstitutions with purified Gβγ and an activated GPCR (e.g., ref. 8). In the absence of
GPCR-mediated nucleotide exchange, it is GDP release (rather than GTP hydrolysis) that is
the rate-limiting step in the Gα nucleotide cycle 9. Thus, to examine the effect of an RGS
protein in accelerating GTP hydrolysis by an isolated Gα subunit in vitro, a single round of
hydrolysis of radiolabelled GTP is usually performed (a.k.a. the “single-turnover GTPase
assay”; ref. 6). This standard assay for measuring RGS domain-mediated GAP activity is
low-throughput and requires discrete steps of [γ-32P]GTP loading onto Gα, protein reactant
admixture (with addition of the critical cofactor Mg2+ to initiate hydrolysis), isolation (in
discrete time intervals) of released [32P]phosphate with activated charcoal precipitation and
centrifugation, and finally scintillation counting. We have described an alternative single-
turnover GTPase assay 10 using a coumarin-labeled, phosphate-binding protein to facilitate
fluorescence-based detection of inorganic phosphate production; however, this method
demands stringent controls on multiple experimental steps to eliminate phosphate
contaminants that interfere with the detection of GTPase activity. Such convoluted protocols
of inorganic phosphate detection are difficult for the non-specialist and especially not suited
for high-throughput screening (HTS) of large compound libraries for RGS domain
inhibitors. We and others have reported alternative, fluorescence-based strategies for
detecting the binding between RGS protein and Gα substrate 11–13, but none has
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specifically facilitated a discrete endpoint measurement of RGS domain-mediated GAP
activity per se.
In order to develop a facile steady-state GTPase assay for RGS domain GAP activity, we
first set out to increase the spontaneous GDP release rate of Gα (koff(GDP)) while also
decreasing its intrinsic rate of GTP hydrolysis (kcat(GTPase)), thereby allowing detection of at
least a five-fold enhancement of steady-state GTP hydrolysis by RGS proteins to provide an
adequate signal-to-noise ratio. Gαi1 and closely related Gα proteins have been the focus of
extensive structure/function studies 14–17, and point mutations that affect both koff(GDP) and
kcat(GTPase) without affecting functional interaction with the RGS domain have been
identified previously 15–18 (e.g., Fig. 1A). Two of the most striking Gα mutations have
been made to the highly-conserved active-site arginine (R178C; ref. 15), which causes a
~100-fold reduction in GTPase activity, and to the alanine residue within the conserved
TCAT loop that contacts the guanine ring (A326S; ref. 16), which results in a ~25-fold
increase in koff(GDP) relative to wildtype yet an identical kcat(GTPase).
To detect RGS protein-accelerated GTPase activity, we adapted a monoclonal antibody and
fluorescent tracer, previously developed for the Transcreener ADP assay 19, for selective
immunodetection of GDP with a fluorescence polarization readout. Measurement of GTPase
activity using this Transcreener GDP assay overcomes the signal-to-noise limitations of
phosphate detection methods and has been validated as a robust HTS method in the case of
ADP detection for kinases and ATPases 20–22. Moreover, because it is a catalytic assay
rather than a substrate binding assay, it should enable detection of all types of modulators of
RGS protein GAP activity, including those that bind at allosteric sites and affect RGS
protein catalytic activity without directly targeting the RGS domain Gα binding-site 23.
In this present study, we tested multiple point-mutant Gαi1 proteins with increased GDP
dissociation and/or decreased GTP hydrolysis rates for their ability to enable detection of
RGS domain GAP activity using a steady-state GTPase assay format (i.e., multiple rounds
of turnover of GTP to GDP). Coupling one of these variants, Gαi1(R178M/A326S), to the
Transcreener GDP detection system has not only allowed facile detection of RGS protein
GAP activity, but was useful in helping establish (along with surface plasmon resonance
spectroscopy) that the mutant Gαi1 interacted with RGS proteins with the same specificity
and affinity as the wildtype Gαi1 protein.
MATERIALS AND METHODS
Chemicals and assay materials
GDP and GTP were purchased from USB Corp. (Cleveland, OH). The monoclonal antibody
and tracer used for GDP detection were developed at BellBrook Labs (Madison, WI) as
described 19, with the tracer comprising ADP conjugated to Alexa Fluor 633 (Invitrogen/
Molecular Probes). Unless otherwise specified, all additional reagents were of the highest
quality obtainable from Sigma (St. Louis, MO) or Fisher Scientific (Hampton, NH).
Protein expression and purification
Wildtype, full-length human Gαi1 and various RGS proteins used in these studies were
expressed in E. coli and purified as previously described 24. Gαi1 point mutants were
created using PCR-based site-directed mutagenesis (QuikChange® II, Stratagene; La Jolla,
CA) on the wildtype pProEXHTb-Gαi1 expression vector; mutagenesis primers were
designed using Stratagene's QuikChange primer-design program and synthesized/PAGE-
purified by Sigma-Genosys. All mutant constructs were sequence verified at Functional
Biosciences LLC (Madison, WI) before protein expression, purification, concentration,
quantitation, and cryopreservation using established protocols 10,24.
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Radiolabeled nucleotide binding and single turnover GTPase assays
Assessments of spontaneous GDP release and single-turnover GTP hydrolysis rates by
wildtype and mutant Gαi1 subunits, using measurements of [35S]GTPγS binding and
[γ-32P]GTP hydrolysis respectively, were conducted exactly as previously described 24,25.
Briefly, for [35S]GTPγS binding by 100 nM of Gαi1 subunits at 20 °C, timed aliquots were
removed, filtered through nitrocellulose, and washed four times with 10 ml of wash buffer
before scintillation counting. Assays were conducted in duplicate, counts were subtracted
from analogous reactions in “non-specific binding” buffer 24, and normalized data plotted as
mean ± S.E.M. For single-turnover [γ-32P]GTP hydrolysis assays, Gαi1 subunits (100 nM)
were pre-bound to [γ-32P]GTP in the absence of Mg2+ for 10 minutes at 30 °C. Reactions
were then initiated by the addition of 10 mM MgCl2 (final concentration) and the production
of 32Pi was measured by activated charcoal filtration and liquid scintillation counting 9,25.
Initial rates obtained by data analysis using GraphPad Prism (La Jolla, CA).
Radiolabeled nucleotide steady-state GTPase assays
Assessments of steady-state [γ-32P]GTP hydrolysis rates by wildtype and mutant Gαi1
subunits were conducted essentially as previously described 26. Briefly, Gαi1 protein was
diluted to 50 nM in a buffer containing 50 mM Tris pH 7.5, 100 mM NaCl, 0.05% C12E10, 1
mM DTT, 5 mM EDTA, 10 mM MgCl2, and 5 μg/ml BSA. Assays were initiated with the
addition of [γ-32P]GTP (and RGS4 if used), aliquots stopped at indicated time intervals, and
free [γ-32P]Pi quantified as previously described 26.
Transcreener GDP assays
Standard curves and GTPase reactions were both run at 30 °C in kinetic mode on a Tecan
Safire2 multiwell reader in Corning® 384-well black round-bottom low-volume polystyrene
non-binding surface microplates (Part # 3676). Fluorescence polarization was read using
635 nm excitation (20 flashes per well) and 670 nm emission. A free tracer reference was set
to 20 mP by adjusting the photomultiplier tubes, and buffer containing GDP antibody alone
was used as a blank for sample and reference wells. EC50 and EC85 values, Hill slopes, and
curves were generated by GraphPad Prism (La Jolla, CA). Unless otherwise indicated,
reactions were run in 20 mM Tris 7.5 pH, 1 mM EDTA, 10 mM MgCl2, 10 μM GTP, 8 μg/
ml GDP antibody, and 2 nM tracer in a final 20 μl volume. GDP antibody was used at a
concentration 85% of the amount required for saturated binding to tracer (i.e., the EC85).
Where shown, polarization data was converted to the amount of GDP produced using
standard curves. Reaction rates were then determined in GraphPad Prism using linear
regression to estimate slope. For GTPase and GAP assays, reactions were started with the
addition of GTP with or without RGS protein.
Compound interference test
To assess the robustness of the Transcreener GDP assay for practical screening applications,
we performed a control screen using the GenPlus library of 960 bioactive molecules from
Microsource Discovery Systems, many of which are approved drugs. GDP assay reagents
(as denoted above) were added to duplicate wells containing 10 μM compound and either 10
μM GTP to mimic no-enzyme control reactions or 9 μM GTP plus 1 μM GDP to mimic
completed enzyme reactions in 1% DMSO.
Pilot screen and counterscreen of GenPlus Library
Screens of the GenPlus library with the Transcreener GDP assay (10 μM final compound
concentration) for modulators of RGS4 GAP activity on Gαi1(R178M/A326S), as well as for
non-specific modulators of intrinsic GTPase activity of Gαi1(R178M/A326S) alone, were
conducted as mentioned above with the following changes. GTPase reactions containing 50
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nM Gαi1(R178M/A326S) with or without 250 nM RGS4 were run in Corning® 384-well
microplates at 30 °C in 20 mM Tris pH 7.5, 1 mM EDTA, 10 mM MgCl2, 10 μM GTP, 12
μg/μl GDP antibody, 2 nM tracer, and 0.5% DMSO (v/v) in a final volume of 20 μl.
Fluorescence polarization was read at 60, 90, 120, and 180 minutes of elapsed reaction time
on a Tecan Safire2 multiwell reader as described above.
Surface plasmon resonance (SPR) spectroscopy
Optical detection of surface plasmon resonance (SPR) was performed using a BIAcore 3000
(GE Healthcare; Piscataway, NJ). Wildtype and mutant Gαi1 proteins were immobilized
onto nickel-nitrilotriacetic acid SPR sensor chips (GE Healthcare) by hexahistidine tag-
mediated capture-coupling as previously described 27. Affinities of RGS proteins for
immobilized Gαi1 proteins were obtained from dose-response sensorgrams using
equilibrium saturation binding analyses as previously described 24.
RESULTS AND DISCUSSION
Profiling multiple Gαi1 point-mutations for nucleotide cycling rate alterations
Using PCR-based site-directed mutagenesis, we created several amino-acid substitutions at
various positions within Gαi1 known to affect koff(GDP) and/or kcat(GTPase) (e.g., Fig. 1).
These mutants included: aspartate, serine, or threonine replacing Ala-326; cysteine, lysine,
or methionine replacing Arg-178; alanine, serine, or valine replacing Thr-181; single
mutants K192A and F336A; and double mutants K192A/F336A, R178C/A326S, R178C/
A326T, R178M/A326S, R178C/A326T, and T181A/A326S. Note that multiple different
substitutions were made at several sites, including amino-acids intended to be more or less
disruptive than the original reported mutation. For instance, R178K and R178M were tested
as more conservative substitutions at the catalytic arginine position relative to the original
R178C variant; it was thought that either of these alternative substitutions might result in a
smaller decrease in kcat(GTPase) than the cysteine replacement which reduces kcat(GTPase) by
two orders of magnitude 15. While the R178C mutation leads to a substantial decrease in
kcat(GTPase), Berman et al. 6 have shown that the single-turnover GTPase rate of this Gα
mutant can still be increased by RGS domain-mediated GAP activity, whereas the more
conventional GTPase-crippling mutation of Q204L renders Gαi1 truly dead in terms of
responsiveness to RGS proteins. Thus, the Gαi1(Q204L) mutant was not pursued in this
study.
Gαi1 mutants were initially profiled for enhanced GDP release and/or reduced GTPase rate
sufficient to see a change in steady-state GTP hydrolysis upon RGS protein addition. This
initial profiling led us to focus on two positions: Arg-178 and Ala-326. Binding of the non-
hydrolyzable GTP analog, [35S]GTPγS, to Gαi1·GDP was used to measure the rate of GDP
dissociation (e.g., Fig. 1B); the prevailing assumption for Gα subunits is that kon for
[35S]GTPγS binding is much more rapid than koff(GDP) 28. Single turnover GTP hydrolysis
measuring 32Pireleased from Gα-bound [γ-32P]GTP – an assay format which is not rate-
limited by GDP dissociation 9 – was used to assess intrinsic kcat rates for the Gαi1 mutants
(e.g., Figure 1C).
As expected, Gαi1 variants with mutation to the active-site catalytic residue Arg-178 had
very low or undetectable levels of GTP hydrolysis, whereas Gαi1(A326S), the single
mutation reported to only affect GDP dissociation, had a GTPase rate similar to wildtype
Gαi1 (Fig. 1C–D). [35S]GTPγS binding assays showed that two variants with mutations only
at the catalytic site, R178M and R178C, had GDP dissociation rates similar to wildtype
Gαi1, whereas introduction of the A326S mutation, either alone or in combination with
R178C, caused a three-fold acceleration in GDP dissociation (Fig. 1B,D). When the A326S
mutation was combined with methionine at Arg-178 (instead of cysteine), the GDP
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dissociation rate increased more than ten-fold over wildtype: from 0.008 min−1 to 0.130
min−1 (Fig. 1D). We currently do not have a precise structural explanation for why the
particular combination of R178M and A326S mutations results in more rapid GDP release
than the single A326S mutation alone; it is not an additive effect, since the singly-mutated
Gαi1(R178M) variant exhibits wildtype GDP dissociation (Fig. 1B). It is interesting to note
that Posner and colleagues, when reporting the crystal structure of the Gαi1(A326S) mutant
16, suggested the presence of an indirect interaction between the Arg-178 and Ser-326
residues (via contacts with nucleotide and Gly-45), thereby providing a possible mechanism
for the functional interaction we have observed here between the R178M and A326S
mutations.
Combined action of two Gαi1 mutations allows steady-state measurement of GAP activity
With the R178M/A326S mutant of Gαi1 demonstrating the largest change in GDP release
rate of all mutants tested, we next examined whether this particular Gαi1 variant would be
affected by RGS domain-mediated GAP activity in steady-state [γ-32P]GTP hydrolysis
assays. Addition of purified RGS4 protein to the Gαi1(R178M/A326S) variant (in the
presence of free [γ-32P]GTP and Mg2+) resulted in a dramatic increase in [32P]Pi detected
over time. In contrast, there was no effect of RGS4 on wildtype Gαi1 in this steady-state
assay (Fig. 2A vs B), as expected given the original report by Berman et al. 6.
Development of a Transcreener GDP assay
The Transcreener platform relies upon highly selective antibodies for detection of
nucleotides produced in enzyme reactions 29. To allow measurement of RGS protein-
mediated acceleration of steady-state GTP hydrolysis in a homogenous format without
radioactivity, a Transcreener assay for GDP was developed (Figure 3A) using a competitive
fluorescence polarization immunoassay format. For this method, a recently-developed
monoclonal antibody that recognizes GDP with >100-fold higher affinity than GTP 19 is
added to the reaction, along with a fluorescent tracer which binds to the antibody with high
affinity. When no free, unlabeled GDP is present in the reaction, the fluorescent tracer
remains antibody-bound and exhibits a high polarization given its high apparent molecular
weight. GDP produced in the reaction displaces the tracer from the antibody, thereby
reducing its apparent molecular weight, increasing its rotational motion, and thus reducing
the degree of polarization of emitted light. A similar Transcreener assay has been widely
used for detection of ADP produced by kinases and other ATP-hydrolyzing proteins (e.g.,
refs. 20–22; reviewed in 29).
Figure 3B shows typical fluorescence polarization standard curves mimicking the
conversion of GTP to GDP by a GTPase. An important aspect of flexibility for a GTPase
assay is the ability to accommodate a range of initial GTP concentrations, so that diverse
enzymes and screening strategies can be employed; therefore, these studies were performed
using different GTP concentrations of 1, 10 and 100 μM. Because the antibody cross-reacts
to some degree with GTP, its concentration must be increased as higher GTP concentrations
are used, in order to buffer for the total guanine nucleotide pool. Thus, for this analysis, the
EC85 concentrations of monoclonal antibody were first determined in the presence of the
indicated initial GTP concentrations (2.2, 12 and 64 μg/ml Ab for 1, 10 and 100 μM GTP,
respectively) and the standard curves for GTP to GDP conversion were performed with 16
replicates at those antibody concentrations. At a GDP concentration equivalent to 10%
conversion of GTP, which is generally considered to be well within the initial velocity
region, polarization shifts of 108, 134, and 148 mP were observed for the 1, 10, and 100 μM
GTP concentration curves, respectively (Fig. 3B). Acceptable Z'-factor values (ref. 30) of
greater than 0.5 were observed down to 2% conversion for the two higher initial GTP
concentrations, and to 5% for the 1 μM initial GTP curve (Fig. 3C), suggesting that the
ZIELINSKI et al. Page 6













Transcreener GDP assay should be capable of very robust detection of GTPase enzyme
initial velocity over at least a 100-fold range of initial GTP concentration.
To assess the potential for compound interference with the Transcreener GDP assay readout,
we performed a control screen (Fig. 3D) with the GenPlus library of 960 bioactive
molecules, many of which are approved drugs. This control screen was done under
conditions mimicking 10% conversion to GDP for a GTPase reaction run at 10 μM initial
GTP concentration. All wells were run in duplicate. The vast majority of the compounds
clustered very tightly around the means for the 10 μM GTP and the 9 μM GTP/1 μM GDP
conditions; the Z'-factor for the no-compound controls in this screen was 0.93. There were
only three compounds in the control screen that caused the signal to vary more than three
standard deviations from the mean: dirithromycin, metazolamide, and lonidamin (Figure
3D). There is no obvious structural similarity between them nor are any of them similar in
structure to guanine nucleotide. These data suggests that compound interference with the
Transcreener GDP assay readout will be minimal.
FP-based detection of RGS protein GAP activity is dependent on two rate-altering
mutations
Having validated the utility of the Transcreener assay in detecting GDP in the presence of
GTP, we next tested its use in measuring RGS protein GAP activity on several rate-altered
Gαi1 variants (Figure 4). In these experiments, the Gαi1 proteins were incubated with and
without the well-characterized, Gαi-directed RGS protein RGS4 31 in the presence of the
Transcreener GDP assay reagents, and plates were read at intervals starting at 15 minutes.
The change in the absolute value of polarization at each time-point (ΔmPt = | mPt(Gαi1) −
mPt(no Gαi1) |) was plotted over a time-course of 6 hours; in addition, the plotted change in
polarization that occurred in the linear region (over the first hour) was converted to GDP
formation using standard curves (akin to those of Figure 3B) and normalized to the amount
of Gαi1 protein present in the reaction, with the resultant initial rates of GTP hydrolysis
calculated from these data shown in Fig. 4E.
The two Gαi1 variants with single mutations at the catalytic arginine only, R178C or
R178M, each had lower steady-state GTPase activity than wildtype Gαi1 and, like wildtype,
were unaffected by RGS4 (GAP factors of 0.9 and 1.2, respectively; Fig. 4E). These results
are expected because their steady-state GTPase rate is limited by slow GDP dissociation.
Conversely, the A326S variant exhibited a much higher steady-state GTPase rate than
wildtype, as expected from its higher koff(GDP) (Fig. 1); however, its steady-state GTPase
rate was unaffected by RGS4 (GAP ratio of 1.1; Fig. 4E), presumably because a further rate
increase in GTPase is limited by koff(GDP). Most importantly, the two double mutants,
R178C/A326S and R178M/A326S, had very low basal steady-state GTPase activities that
became demonstrably higher in the presence of RGS4 (e.g., Fig. 4A–B); the GAP effect on
Gαi1(R178M/A326S) was greater than with the Gαi1(R178C/A326S) variant (GAP factors
of 6.5 and 3.6, respectively; Fig. 4E). Given its high GAP factor response in both the steady-
state [γ-32P]GTP hydrolysis assay (Fig. 2) and the Transcreener GDP assay (Fig. 4), the
Gαi1(R178M/A326S) variant was used in subsequent analyses.
Gαi1(R178M/A326S) interacts with RGS proteins with same affinity and specificity as
wildtype
A possible concern about the use of a mutated Gα protein for RGS protein GAP assays is
that the mutation(s) could disrupt the global fold of Gα or, at the very least, affect the
disposition of the switch regions and other surface contact points to which RGS proteins
interact 24,31, thereby altering the normal affinity and specificity that RGS proteins show
for their various Gα substrates. The two point mutations of R178M and A326S are interior
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to the guanine nucleotide binding pocket (Figure 5), but could nevertheless affect the RGS
domain interaction surface.
To test for this possibility, we used SPR to compare the binding interactions of RGS2 and
RGS16 with wildtype Gαi1 versus the Gαi1(R178M/A326S) variant. Multiple previous
studies 8,24,32 have established that RGS2, a potent GAP for Gαq, does not interact with
wildtype Gαi1 in vitro; this same lack of interaction was observed with the Gαi1(R178M/
A326S) mutant (data not shown). Conversely, RGS16 is known to be a Gαi-interacting RGS
protein 24, and was found by SPR to bind equivalently to immobilized wildtype Gαi1 and
Gαi1(R178M/A326S) proteins (Fig. 6). This equivalence included RGS16 only interacting
with high affinity to the Gα subunits in their transition state-mimetic form (namely, Gα in
complex with GDP and aluminum tetrafluoride 31). These binding results suggest that no
long-range perturbations have been made to the RGS domain interaction sites on Gαi1 by the
two rate-altering mutations of R178M and A326S.
Using the Transcreener GDP assay, we performed an additional test of the Gαi1(R178M/
A326S) variant to control for any unintended changes the two point mutations could have
engendered within Gα to alter its interaction specificity with various RGS proteins. With the
same RGS protein spectrum used in the SPR binding experiments, we found that RGS2
(highly selective for Gαq over Gαi substrates) had no effect on increasing steady-state
GTPase activity of Gαi1(R178M/A326S), whereas RGS16 increased steady-state GTPase
activity 12-fold over the basal rate (Fig. 7).
Pilot screen for inhibitors of RGS4 GAP activity on Gαi1(R178M/A326S)
Given the robust performance of the Transcreener GDP assay in the control screen for
potential compound interference (Fig. 3D) and evidence that the two mutations to Gαi1
affected neither the affinity nor specificity of the Gα/RGS domain interaction (Figs. 6 and
7), we proceeded to a pilot screen with Gαi1(R178M/A326S) and RGS4 using the GenPlus
library of 960 bioactive molecules (Fig. 8). The screening window was first optimized by
varying the concentrations of Gα and RGS protein inputs; at 50 nM Gαi1(R178M/A326S)
and 250 nM RGS4, a maximal signal to background difference of 112 mP units was
obtained after 120 minutes of elapsed reaction time before FP measurement. The thiol-
reactive compound CCG-4986 was used in the screen as a positive control for RGS4
inhibition 13,33. The GenPlus library screen was conducted with Gαi1(R178M/A326S) and
RGS4 (Fig. 8A); a separate counterscreen of the library was performed with Gαi1(R178M/
A326S) and no RGS4 (Fig. 8B) to identify compounds having either non-specific effects or
modifying Gαi1 GTPase activity (rather than RGS4 GAP activity per se).
Z'-factors of 0.60, 0.83, 0.83, and 0.82 were obtained at 60, 90, 120, and 180 minutes
elapsed reaction time, as calculated based on data from control wells containing either
Gαi1(R178M/A326S) only or Gαi1(R178M/A326S) plus RGS4. Note that these Z'-factor
values reflect only the RGS4-dependent increase in GTPase activity, and not the total
observed GTPase activity relative to no-enzyme controls. The Z-factor for the GenPlus
library screen at the 120 minute time point (shown in Fig. 8A) was 0.73, which was
calculated by excluding values from wells containing hit compounds. Of the 960 compounds
in the GenPlus library, 17 compounds were initially considered hits in the RGS4/Gα screen:
i.e., those data points that fell outside the μ±3σ range. However, ten of these 17 hits also
resulted in a greater than ±3σ change in the mean signal within the Gα-only counterscreen
and thus were excluded because these compounds are likely either affecting the Gα subunit
or otherwise interfering with the assay. Thus the RGS4-specific hit rate was 0.7%: seven
compounds from the 960 compound library exhibited an modulatory effect on GDP
production that was specific to RGS4-stimulated GTPase activity (Fig. 8A vs 8B). Six
compounds (id # 62, 63, 244, 413, 524, 812) exhibited an RGS4-specific inhibitory effect
ZIELINSKI et al. Page 8













(i.e., a change in polarization greater than the [mean + 3 S.D.] signal threshold) and one
compound (#596) exhibited an RGS4-specific activating effect on GDP production (i.e., a
change in polarization less than the [mean − 3 S.D.] signal threshold). This hit rate may be
artificially high in this pilot screen given that the collection of compounds surveyed
(GenPlus library) is not a diverse sampling of chemical space but a collection of US,
European, and Japanese approved drugs and other bioactive compounds. As expected 13,33,
the thiol-reactive RGS4 inhibitor CCG-4986 consistently exhibited inhibition of RGS4-
stimulated GDP production (Fig. 8A).
To our knowledge, the combined use of a GDP detection assay with a rate-altered Gα
subunit represents a unique strategy to the detection of RGS protein GAP activity. Even
though the two primary components of Gα catalysis, GTP hydrolysis rate and product
release, were altered significantly by mutation, the resultant Gα subunits still served as
functional substrates for the GTPase-accelerating activity of RGS proteins. Using this
double mutation strategy to develop a steady-state RGS protein GAP assay that is easy for
the non-specialist to perform, and is well-suited for HTS, removes a major technical barrier
preventing the exploration of RGS proteins as therapeutic targets. Moreover, Gαi1 is a
substrate for the GAP activity of several RGS protein family members 24 in addition to
those we have tested here; thus, the reagents and methods that we have described should
have broad applicability across the protein family. Employing the rate-altered Gαi1(R178M/
A326S) mutant in a homogeneous, end-point-based, enzymatic HTS assay will not only be
useful in screening for RGS protein inhibitors but, unlike existing assays based on the RGS
domain/Gα binding interaction 11–13, this enzymatic assay should also facilitate
identification of small molecule activators of RGS domain-mediated GAP activity. The lipid
moiety phosphatidylinositol-3,4,5-trisphophate (PIP3) has been shown to bind to, and
thereby inhibit in an allosteric fashion, the GAP activity of select RGS domains such as that
of RGS4 23; Ca2+/calmodulin reverses this PIP3.-mediated inhibition by competing for the
PIP3-binding site 23. A small molecule targeting this site of allosteric modulation over RGS
domain GAP activity could potentially be quite valuable therapeutically in
pathophysiological situations which may arise from a loss of RGS protein activity, such as
RGS2 in hypertension 34 and RGS4 in schizophrenia 35.
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Figure 1. Increased GDP release and decreased GTP hydrolysis of the Gαi1(R178M/A326S)
mutant compared to wildtype Gαi1 and single point-mutants, as measured by [35S]GTPγS
binding and single-turnover [γ-32P]GTP hydrolysis, respectively
(A) Point mutations to Gαi-family subunits previously reported in the literature 15–18 to
alter intrinsic GTP hydrolysis and GDP dissociation rates. (B) Binding of [35S]GTPγS to
wildtype or indicated mutant Gαi1 subunits. (C) Single-turnover GTP hydrolysis activities of
wildtype or indicated mutant Gαi1 subunits. (D) Initial rates of GTP binding and hydrolysis
for the Gαi1(R178M/A326S) mutant, as well as other Gαi1 point mutants derived from data
similar to that of panels B and C.
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Figure 2. RGS4 GAP activity is observed as an increase in steady-state GTP hydrolysis only for
the rate-altered Gαi1(R178M/A326S) variant
Time courses of steady-state [γ-32P]GTP hydrolysis by 50 nM Gαi1(R178M/A326S) mutant
(A) or 50 nM wildtype Gαi1 (B) in the presence or absence of 250 nM RGS4 at 20°C.
Results are the mean (± S.E.M.) of duplicate samples.
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Figure 3. Fluorescence polarization immunoassay for the detection of GDP
(A) Schematic representation of methodology underlying the Transcreener GDP assay as
applied to steady-state GTP hydrolysis (and resultant GDP production) by a rate-altered Gα
protein. Fluorescent tracer is illustrated with a jagged oval; when bound to the GDP-
selective monoclonal antibody, emitted light remains polarized, whereas there is low
polarization of emitted light when tracer is displaced by free GDP. (B) The Transcreener
GDP assay was used to generate standard curves for conversion of GTP into GDP at initial
GTP concentrations of 1, 10, and 100 μM using appropriate EC85 concentrations of GDP
antibody established for these initial GTP concentrations (2.2, 12, and 64 μg/mL,
respectively). (C) Z'-factor values, reflecting both assay signal window and signal variability
30, were determined in 16 replicates for each of the points in the GDP-detection standard
curves presented in panel B. Although the assay window was reduced at lower percent
conversions (e.g., 57 mP for 3% conversion to GDP of 10 μM initial GTP; panel B),
acceptable Z'-factors 30 of >0.5 were observed down to 2% conversion for the two higher
initial GTP concentrations and to 5% for the 1 μM initial GTP curve, given the very low
signal variability. (D) Control screen using the 960 compound GenPlus library. Assay
components were added to duplicate wells containing 10 μM compound and either 10 μM
GTP (to mimic no-enzyme control reactions) or 9 μM GTP plus 1 μM GTP (to mimic
completed GTPase reactions). The range of signal observed (3 standard deviations about the
mean; “μ±3σ”) in each condition is demarked with a dotted grey line.
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Figure 4. RGS4 increases the steady-state GTPase activity of Gαi1(R178M/A326S) but not
wildtype Gαi1, as measured using the Transcreener GDP assay and reported in absolute change
in polarization (left panels) and GDP produced per Gα protein in reaction (right panels)
R178M/A326S double-mutant (A,B) and wildtype (C,D) Gαi1 proteins were present at 50
nM final concentration. Dashed lines represent reactions conducted in the presence, and
solid lines (“mock”) in the absence, of 250 nM RGS4 protein. (A,C) Change in polarization
(ΔmP) at each time-point for indicated Gαi1 protein was calculated as ΔmP = |mP(Gαi1) −
mP(no Gαi1)|. (B,D) Data from panels A and C were converted to GDP produced per mol of
input Gαi1 using previously established standard curves for GDP detection in the presence of
GTP (e.g., Figure 3B). (E) Summary of initial rates obtained by the Transcreener GDP assay
for each Gαi1 mutant tested. “GAP factor” is defined as the ratio between steady-state
GTPase rate in the presence of RGS protein and steady-state GTPase rate in the absence of
RGS protein.
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Figure 5. Structural features of the RGS16/Gαi1·GDP·AlF −4 complex highlighting the locations
of Arg-178 and Ala-326 residue positions mutated in the Gαi1(R178M/A326S) variant
The RGS16/Gα complex (PDB id 2IK8; ref. 24), was rendered using PyMOL with the
RGS16 RGS domain in orange and Gαi1 protein in blue, respectively. Gαi1 switch regions
are depicted in grey; switches one and two (SI, SII) are visible in the foreground, whereas
switch three is in the background and thus unlabeled. GDP is shown in magenta, the AlF ‒4
ion is red, and Mg2+ ion is depicted as a yellow sphere. Residues arginine-178 and
alanine-326 are rendered as `sticks' in green with CPK atomic coloring (nitrogen = blue,
oxygen = red).
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Figure 6. RGS16 binds equivalently to wildtype Gαi1 and the rate-altered G αi1 (R178M/A326S)
mutant
(A,B) Sensorgrams derived from 600 second injections of various concentrations (3 nM to
10 μM) of RGS16 over SPR biosensors of immobilized (A) wildtype Gαi1·GDP·AlF ‒4 or
(B) Gαi1(R178M/A326S)·GDP·AlF ‡4. SPR experiments were also conducted with both
Gαi1 subunits in their inactive, GDP-bound state (data not shown). (C,D) Resultant
sensorgrams were used in equilibrium saturation binding analyses (as previously described
24) to derive dissociation constants (KD values). RGS16 bound to wildtype
Gαi1·GDP·AlF −4 with a dissociation constant of 124 nM (95% C.I. of 76–174 nM; panel
C), whereas RGS16 bound to Gαi1(R178M/A326S)·GDP·AlF −4 with a dissociation
constant of 115 nM (64–166 nM; panel D). Note that interactions were not observed (for
either Gα subunit) when the Gα was GDP-bound (as expected; refs. 24,31), nor when RGS2
was injected (data not shown).
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Figure 7. The steady-state GTPase activity of Gαi1(R178M/A326S) is increased by RGS4 and
RGS16, but not by the Gαq-selective RGS2
Transcreener GDP assays were performed as in Figure 4, using 250 nM of the indicated
RGS protein. Moles of GDP produced per mol input Gαi1(R178M/A326S) protein were first
plotted over time using GraphPad Prism and linear regression performed to determine
steady-state GTPase rates. Presented bar graph denotes GAP factors derived from these
steady-state GTPase rates.
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Figure 8. Pilot screen and counterscreen using the 960 compound GenPlus library
Transcreener GDP assay components were added to wells containing 50 nM Gαi1 (R178M/
A326S) with (panel A) or without (panel B) 250 nM RGS4 protein and either 10 μM
compound (in 0.5% [v/v] final concentration of DMSO), 150 μM of reactive RGS4 inhibitor
CCG-4986, or 0.5% DMSO only, as indicated in the legends. The range of signal observed
(three standard deviations [σ] about the mean [μ]) is denoted by the dashed lines for the 960
compound library screen using RGS4 and Gαi1 (R178M/A326S) (black; panel A, coefficient
of variation [CV%] = 8.8%) and library counterscreen using Gαi1 (R178M/A326S) alone
(gray; panel B, CV% = 3.0%). Data in panel A was obtained at 120 minutes of elapsed
reaction time; data in panel B was obtained after 210 minutes of elapsed reaction time, given
the slower GTPase (and GDP production) rate of Gαi1 (R178M/A326S) in the absence of
RGS4 GAP activity.
ZIELINSKI et al. Page 19
J Biomol Screen. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
